LEADER 02916nam 22006615 450 001 9910298324703321 005 20200706210448.0 010 $a3-319-00978-8 024 7 $a10.1007/978-3-319-00978-0 035 $a(CKB)2550000001166534 035 $a(EBL)1592324 035 $a(OCoLC)897576910 035 $a(SSID)ssj0001066480 035 $a(PQKBManifestationID)11585485 035 $a(PQKBTitleCode)TC0001066480 035 $a(PQKBWorkID)11067048 035 $a(PQKB)10347637 035 $a(MiAaPQ)EBC1592324 035 $a(DE-He213)978-3-319-00978-0 035 $a(PPN)176103503 035 $a(EXLCZ)992550000001166534 100 $a20131107d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aMolecular Vaccines $eFrom Prophylaxis to Therapy - Volume 2 /$fedited by Matthias Giese 205 $a1st ed. 2014. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2014. 215 $a1 online resource (434 p.) 300 $aDescription based upon print version of record. 311 $a3-319-00977-X 311 $a1-306-16576-8 320 $aIncludes bibliographical references and index. 327 $aNon-infectious and non-cancer vaccines -- Adjuvants and nanotechnology -- In silico and delivery systems -- Patenting, manufacturing, registration. 330 $aThis title discusses all aspects of non-infectious and non-cancer? so called NINC ? vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. Practical perspectives of patentability of vaccines are discussed. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application. 606 $aVaccines 606 $aImmunology 606 $aMolecular biology 606 $aVaccine$3https://scigraph.springernature.com/ontologies/product-market-codes/B16010 606 $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 615 0$aVaccines. 615 0$aImmunology. 615 0$aMolecular biology. 615 14$aVaccine. 615 24$aImmunology. 615 24$aMolecular Medicine. 676 $a610 676 $a611.01816 676 $a615.372 676 $a615372 702 $aGiese$b Matthias$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910298324703321 996 $aMolecular Vaccines$92537239 997 $aUNINA